1
|
Shirokova O, Zaborskaya O, Pchelin P, Kozliaeva E, Pershin V, Mukhina I. Genetic and Epigenetic Sexual Dimorphism of Brain Cells during Aging. Brain Sci 2023; 13:brainsci13020195. [PMID: 36831738 PMCID: PMC9954625 DOI: 10.3390/brainsci13020195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Revised: 01/16/2023] [Accepted: 01/18/2023] [Indexed: 01/27/2023] Open
Abstract
In recent years, much of the attention paid to theoretical and applied biomedicine, as well as neurobiology, has been drawn to various aspects of sexual dimorphism due to the differences that male and female brain cells demonstrate during aging: (a) a dimorphic pattern of response to therapy for neurodegenerative disorders, (b) different age of onset and different degrees of the prevalence of such disorders, and (c) differences in their symptomatic manifestations in men and women. The purpose of this review is to outline the genetic and epigenetic differences in brain cells during aging in males and females. As a result, we hereby show that the presence of brain aging patterns in males and females is due to a complex of factors associated with the effects of sex chromosomes, which subsequently entails a change in signal cascades in somatic cells.
Collapse
Affiliation(s)
- Olesya Shirokova
- Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950, Russia
- Correspondence:
| | - Olga Zaborskaya
- Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950, Russia
| | - Pavel Pchelin
- Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950, Russia
- Institute of Biology and Biomedicine, Lobachevsky State University, 23 Gagarin Avenue, Nizhny Novgorod 603002, Russia
| | - Elizaveta Kozliaeva
- Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950, Russia
| | - Vladimir Pershin
- Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950, Russia
- Institute of Biology and Biomedicine, Lobachevsky State University, 23 Gagarin Avenue, Nizhny Novgorod 603002, Russia
| | - Irina Mukhina
- Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod 603950, Russia
- Institute of Biology and Biomedicine, Lobachevsky State University, 23 Gagarin Avenue, Nizhny Novgorod 603002, Russia
| |
Collapse
|
2
|
Labombarda F, Bellini M. Brain and spinal cord trauma: what we know about the therapeutic potential of insulin growth factor 1 gene therapy. Neural Regen Res 2023; 18:253-257. [PMID: 35900399 PMCID: PMC9396494 DOI: 10.4103/1673-5374.343902] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Although little attention has been paid to cognitive and emotional dysfunctions observed in patients after spinal cord injury, several reports have described impairments in cognitive abilities. Our group also has contributed significantly to the study of cognitive impairments in a rat model of spinal cord injury. These findings are very significant because they demonstrate that cognitive and mood deficits are not induced by lifestyle changes, drugs of abuse, and combined medication. They are related to changes in brain structures involved in cognition and emotion, such as the hippocampus. Chronic spinal cord injury decreases neurogenesis, enhances glial reactivity leading to hippocampal neuroinflammation, and triggers cognitive deficits. These brain distal abnormalities are recently called tertiary damage. Given that there is no treatment for Tertiary Damage, insulin growth factor 1 gene therapy emerges as a good candidate. Insulin growth factor 1 gene therapy recovers neurogenesis and induces the polarization from pro-inflammatory towards anti-inflammatory microglial phenotypes, which represents a potential strategy to treat the neuroinflammation that supports tertiary damage. Insulin growth factor 1 gene therapy can be extended to other central nervous system pathologies such as traumatic brain injury where the neuroinflammatory component is crucial. Insulin growth factor 1 gene therapy could emerge as a new therapeutic strategy for treating traumatic brain injury and spinal cord injury.
Collapse
|
3
|
Champarini LG, Herrera ML, Comas Mutis RG, Espejo PJ, Molina VA, Calfa GD, Hereñú CB. Effect of intra-BLA overexpression of IGF-1 on the expression of a contextual fear memory trace. Hippocampus 2022; 32:765-775. [PMID: 36000813 DOI: 10.1002/hipo.23465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 08/04/2022] [Accepted: 08/08/2022] [Indexed: 11/08/2022]
Abstract
Growth factors, such as insulin-like growth factor 1 (IGF-1), among others are known for their critical involvement in learning and memory processes. IGF-1 regulates cognitive functions, synapse density, neurotransmission, and adult neurogenesis and induces structural and synaptic plasticity-specific changes. Although IGF-1 has been suggested to participate in different memory processes, its role in memories associated with negative emotional experiences still remains to be elucidated. The principal aim of the present study was to test whether IGF-1 overexpression using adenoviral vectors in basolateral amygdala (BLA) influences both the expression and formation of contextual fear memory, as well as the hippocampal structural plasticity associated with such memory trace. We found that IGF-1 overexpression promotes the formation and expression of a specific contextual fear memory trace, and such effect persisted at least 7 days after recall. Moreover, the overexpression of this growth factor in BLA upregulates the activation of the ERK/MAPK pathway in this brain structure. In addition, intra-BLA IGF-1 overexpression causes dorsal hippocampus (DH) structural plasticity modifications promoting changes in the proportion of mature dendritic spines in the CA1 region, after a weak conditioning protocol. The present findings contribute to the knowledge underlying BLA-DH trace memory of fear and reveal important new insights into the neurobiology and neurochemistry of fear acquisition modulated by IGF-1 overexpression. The understanding of how IGF-1 modulates the formation of a fear contextual trace may pave the way for the development of novel therapeutic strategies focused on fear, anxiety, and trauma-related disorders.
Collapse
Affiliation(s)
- Leandro Gabriel Champarini
- Departamento de Farmacología, Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Cordoba, Argentina
| | - Macarena Lorena Herrera
- Departamento de Farmacología, Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Cordoba, Argentina
| | - Ramiro Gabriel Comas Mutis
- Departamento de Farmacología, Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Cordoba, Argentina
| | - Pablo Javier Espejo
- Departamento de Farmacología, Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Cordoba, Argentina
| | - Victor Alejandro Molina
- Departamento de Farmacología, Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Cordoba, Argentina
| | - Gastón Diego Calfa
- Departamento de Farmacología, Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Cordoba, Argentina
| | - Claudia Beatriz Hereñú
- Departamento de Farmacología, Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Cordoba, Argentina
| |
Collapse
|
4
|
IGF1 Gene Therapy Reversed Cognitive Deficits and Restored Hippocampal Alterations After Chronic Spinal Cord Injury. Mol Neurobiol 2021; 58:6186-6202. [PMID: 34463925 DOI: 10.1007/s12035-021-02545-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Accepted: 08/22/2021] [Indexed: 10/20/2022]
Abstract
The hippocampus is implicated in the generation of memory and learning, processes which involve extensive neuroplasticity. The generation of hippocampal adult-born neurons is particularly regulated by glial cells of the neurogenic niche and the surrounding microenvironment. Interestingly, recent evidence has shown that spinal cord injury (SCI) in rodents leads to hippocampal neuroinflammation, neurogenesis reduction, and cognitive impairments. In this scenario, the aim of this work was to evaluate whether an adenoviral vector expressing IGF1 could reverse hippocampal alterations and cognitive deficits after chronic SCI. SCI caused neurogenesis reduction and impairments of both recognition and working memories. We also found that SCI increased the number of hypertrophic arginase-1 negative microglia concomitant with the decrease of the number of ramified surveillance microglia in the hilus, molecular layer, and subgranular zone of the dentate gyrus. RAd-IGF1 treatment restored neurogenesis and improved recognition and working memory impairments. In addition, RAd-IGF1 gene therapy modulated differentially hippocampal regions. In the hilus and molecular layer, IGF1 gene therapy recovered the number of surveillance microglia coincident with a reduction of hypertrophic microglia cell number. However, in the neurogenic niche, IGF1 reduced the number of ramified microglia and increased the number of hypertrophic microglia, which as a whole expressed arginase-1. In summary, RAd-IGF1 gene therapy might surge as a new therapeutic strategy for patients with hippocampal microglial alterations and cognitive deficits such as those with spinal cord injury and other neurodegenerative diseases.
Collapse
|
5
|
Herrera ML, Bandín S, Champarini LG, Hereñú CB, Bellini MJ. Intramuscular insulin-like growth factor-1 gene therapy modulates reactive microglia after traumatic brain injury. Brain Res Bull 2021; 175:196-204. [PMID: 34339780 DOI: 10.1016/j.brainresbull.2021.07.023] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 06/07/2021] [Accepted: 07/27/2021] [Indexed: 12/23/2022]
Abstract
Reactive gliosis is a key feature and an important pathophysiological mechanism underlying chronic neurodegeneration following traumatic brain injury (TBI). In this study, we have explored the effects of intramuscular IGF-1 gene therapy on reactive gliosis and functional outcome after an injury of the cerebral cortex. Young adult male rats were intramuscularly injected with a recombinant adenoviral construct harboring the cDNA of human IGF-1 (RAd-IGF1), with a control vector expressing green fluorescent protein (RAd-GFP) or PBS as control. Three weeks after the intramuscular injections of adenoviral vectors, animals were subjected to a unilateral penetrating brain injury. The data revealed that RAd-IGF1 gene therapy significantly increased serum IGF1 levels and improved working memory performance after one week of TBI as compared to PBS or RAd-GFP lesioned animals. At the same time, when we analyzed the effects of therapy on glial scar formation, the treatment with RAd-IGF1 did not modify the number of glial fibrillary acidic protein (GFAP) positive cells, but we observed a decrease in vimentin immunoreactive astrocytes at 7 days post-lesion in the injured hemisphere compared to RAd-GFP group. Moreover, IGF-1 gene therapy reduced the number of Iba1+ cells with reactive phenotype and the number of MHCII + cells in the injured hemisphere. These results suggest that intramuscular IGF-1 gene therapy may represent a new approach to prevent traumatic brain injury outcomes in rats.
Collapse
Affiliation(s)
- Macarena Lorena Herrera
- Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Farmacología, Córdoba, Argentina; Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Córdoba, Argentina; Universidad Nacional de La Plata, Facultad de Ciencias Médicas, Buenos Aires, Argentina; Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP-CONICET), La Plata, Argentina
| | - Sandra Bandín
- Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), 28002 Madrid, Spain
| | - Leandro Gabriel Champarini
- Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Farmacología, Córdoba, Argentina; Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Córdoba, Argentina
| | - Claudia Beatriz Hereñú
- Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Farmacología, Córdoba, Argentina; Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Córdoba, Argentina
| | - Maria Jose Bellini
- Universidad Nacional de La Plata, Facultad de Ciencias Médicas, Buenos Aires, Argentina; Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP-CONICET), La Plata, Argentina.
| |
Collapse
|
6
|
Herrera ML, Basmadjian OM, Falomir‐Lockhart E, Dolcetti FJ, Hereñú CB, Bellini MJ. Sex frailty differences in ageing mice: Neuropathologies and therapeutic projections. Eur J Neurosci 2020; 52:2827-2837. [DOI: 10.1111/ejn.14703] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 02/04/2020] [Accepted: 02/09/2020] [Indexed: 12/15/2022]
Affiliation(s)
- Macarena Lorena Herrera
- Departamento de Farmacología Facultad de Ciencias Químicas Instituto de Farmacología Experimental Córdoba (IFEC‐CONICET) Universidad Nacional de Córdoba Córdoba Argentina
- Facultad de Ciencias Médicas Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP‐CONICET) Universidad Nacional de La Plata Buenos Aires Argentina
| | - Osvaldo Martin Basmadjian
- Departamento de Farmacología Facultad de Ciencias Químicas Instituto de Farmacología Experimental Córdoba (IFEC‐CONICET) Universidad Nacional de Córdoba Córdoba Argentina
| | - Eugenia Falomir‐Lockhart
- Facultad de Ciencias Médicas Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP‐CONICET) Universidad Nacional de La Plata Buenos Aires Argentina
| | - Franco Juan‐Cruz Dolcetti
- Facultad de Ciencias Médicas Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP‐CONICET) Universidad Nacional de La Plata Buenos Aires Argentina
| | - Claudia Beatriz Hereñú
- Departamento de Farmacología Facultad de Ciencias Químicas Instituto de Farmacología Experimental Córdoba (IFEC‐CONICET) Universidad Nacional de Córdoba Córdoba Argentina
| | - María José Bellini
- Facultad de Ciencias Médicas Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP‐CONICET) Universidad Nacional de La Plata Buenos Aires Argentina
| |
Collapse
|